Skip to content
    Perceptive Advisors logo

    Perceptive Advisors

    New York, New York, United StatesFounded 1999
    www.perceptivelife.comLinkedIn
    Biotech & Life SciencesHealthcare

    Perceptive Advisors is an American investment firm founded in 1999 and headquartered in New York City, focused on making public and private investments in the healthcare and biotechnology industries. Its venture capital arm, Perceptive Xontogeny, targets early-stage life sciences companies at the seed and Series A stages.

    43% of their portfolio is in Biotech & Life Sciences. Deal activity increased 38% year-over-year (11 deals in the last 12 months). Average disclosed round size is $93.6M (across 194 rounds with reported amounts).

    Find people at Perceptive Advisors on Goldilocks AI

    Portfolio

    164

    Fund Size

    $515M

    Top Stage

    Series B

    Last 12 Mo

    11

    Team

    BS

    Bill Schwieterman, MD

    Managing Director, Regulatory

    David Ingraldi

    David Ingraldi

    Managing Director, Investor Relations & Marketing

    FC

    Fred Callori

    Managing Director

    SM

    Sean Mansoory

    Managing Director

    SN

    Sean Nelson

    Managing Director & Head of Wealth

    Craig Yeshion, MD

    Craig Yeshion, MD

    Director of Research

    David Kim

    David Kim

    Tax Director

    PM

    Patrick Morrow

    Director of Investor Relations & Marketing

    KL

    Kriti Lall

    Principal, Biotechnology

    AH

    Andrés Horcajo

    Vice President, Investor Relations & Marketing

    Carlos Vazquez

    Carlos Vazquez

    Vice President

    ES

    Emerson Shiu

    Vice President, Medical Devices/Diagnostics/MedTech

    Portfolio Breakdown

    Stage Distribution

    Sector Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    219 investments
    CompanyRoundAmountDate
    Crystalys Therapeutics Inc logoCrystalys Therapeutics IncSeries B$130MJul 2026
    CCereVasc, Inc.Series C$85MJun 2026
    Pulmonx logoPulmonxSeries D$40MMay 2026
    Giant logoGiantSeed$8MFeb 2026
    Novig logoNovigSeries B$75MFeb 2026
    Novig logoNovigSeries B$75MFeb 2026
    Talkiatry logoTalkiatrySeries D$210MFeb 2026
    OOruka Therapeutics IncUnknown$180MSep 2025
    Dispatch logoDispatchSeries A$18MSep 2025
    Mercy BioAnalytics logoMercy BioAnalyticsSeries B$59MSep 2025
    Galvanize Therapeutics logoGalvanize TherapeuticsSeries C$100MSep 2025
    IInstaLILYSeries A$25MAug 2025
    Novig logoNovigSeries A$18MAug 2025
    Novig logoNovigSeries A$18MAug 2025
    Crescent Biopharma logoCrescent BiopharmaGrowth$200MJun 2025
    Korl logoKorlSeed$5MMay 2025
    Contineum Therapeutics logoContineum TherapeuticsSeries B$30MJan 2025
    Damora Therapeutics logoDamora TherapeuticsUnknown$284.9MJan 2025
    Freenome logoFreenomeUnknown$330MJan 2025
    IInstaLILYSeries A$25MJan 2025
    MMIVIUnknown$9.3MJan 2025
    RAPT Therapeutics logoRAPT TherapeuticsSeries D$150MDec 2024
    Axonis logoAxonisSeries A$115MOct 2024
    Inventiva logoInventivaUnknown—Oct 2024
    Talkiatry logoTalkiatrySeries C$130MJun 2024
    Page 1 of 9

    Top Co-Investors

    RA Capital Management37 shared
    Cormorant Asset Management29 shared
    OrbiMed26 shared
    Surveyor Capital23 shared
    Redmile Group23 shared
    Viking Global Investors23 shared
    GV18 shared
    T. Rowe Price17 shared
    Casdin Capital17 shared
    The Invus Group, LLC17 shared
    Foresite Capital16 shared
    Rock Springs Capital15 shared
    Wellington Management15 shared
    Logos Capital15 shared
    Alexandria Venture Investments14 shared
    Deerfield12 shared
    Avidity Partners12 shared
    Perceptive Xontogeny Venture Fund12 shared
    New Enterprise Associates11 shared
    ArrowMark Partners11 shared

    Last updated: 7 October 2026